Drug intelligence / Profile preview

Pearl-103

Development stage: Preclinical
Lead developer: PearlsInMires
Modality: Small Molecules
Administration: Oral

Overview

Pearl-103 is a small molecule therapeutic candidate currently in preclinical development by PearlsInMires for the treatment of solid tumors. The drug is designed to target AXIN and CTNNB1 (beta-catenin), key components of the Wnt/beta-catenin signaling pathway. Dysregulation of this pathway is a frequent driver in various cancers, and Pearl-103 aims to address these malignancies by modulating the activity of the beta-catenin destruction complex or its downstream signaling. As of 2024, the program is in the preclinical stage with patent applications anticipated through 2025.

Other names: Pearl-103Pearl103Pearl 103

Targets

CTNNB1 (Beta-catenin)AXIN1 (Axis inhibition protein 1)

Beyond the preview

Go deeper on Pearl-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pearl-103.

Explore the full profile